November 29, 2016 - By Winifred Garcia
A few days ago, the Chairman & CEO of United Therapeutics Corp, Mr. Martine Rothblatt, made a sale of amount of shares – 1,233, amounting to $163,749 US Dollars, based on an average weighted cost of $132.8 of a share. Martine is trying to decrease her company’s share, same as she did in the last month. She unloaded another 3,744 shares worth $473,507 USD. For more details of this trade please refer to the Security and Exchange Commission’s filing accessible online here. Martine Rothblatt right now holds 1.60% of United Therapeutics Corp’s market cap with ownership of 648,797 shares.
Out of 6 analysts covering United Therapeutics (NASDAQ:UTHR), 2 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 33% are positive. $244 is the highest target while $95 is the lowest. The $174 average target is 37.47% above today’s ($126.57) stock price. United Therapeutics has been the topic of 10 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Argus Research maintained the shares of UTHR in a report on Friday, July 31 with “Buy” rating. The rating was maintained by Cowen & Co with “Outperform” on Monday, August 17. The firm has “Hold” rating given on Tuesday, May 24 by Argus Research. The rating was downgraded by H.C. Wainwright on Wednesday, June 15 to “Neutral”. The firm has “Neutral” rating by Ladenburg Thalmann given on Friday, April 29. The firm has “Underweight” rating by Barclays Capital given on Tuesday, November 29. RBC Capital Markets maintained the shares of UTHR in a report on Wednesday, July 29 with “Sector Perform” rating. The firm has “Buy” rating by Ladenburg Thalmann given on Friday, October 28. On Friday, February 26 the stock rating was maintained by Barclays Capital with “Equal-Weight”.
Insitutional Activity: The institutional sentiment decreased to 0.89 in Q2 2016. Its down 0.11, from 1 in 2016Q1. The ratio dropped, as 52 funds sold all United Therapeutics Corporation shares owned while 121 reduced positions. 39 funds bought stakes while 134 increased positions. They now own 47.41 million shares or 3.79% less from 49.28 million shares in 2016Q1.
New Amsterdam Prtnrs Ltd Llc Ny holds 1.09% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR) for 42,269 shares. First Citizens Fincl Bank And has invested 0.03% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR). Frontier Management Ltd Liability last reported 68,918 shares in the company. The California-based California State Teachers Retirement System has invested 0.02% in United Therapeutics Corporation (NASDAQ:UTHR). Mutual Of America Capital Mgmt Ltd Liability holds 0.08% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR) for 33,749 shares. Oregon Public Employees Retirement Fund holds 18,782 shares or 0.04% of its portfolio. Ibm Retirement Fund holds 0.02% or 4,451 shares in its portfolio. Morgan Stanley holds 0.02% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR) for 396,174 shares. Alps Advsr Incorporated accumulated 3,341 shares or 0% of the stock. Tealwood Asset Management Inc accumulated 23,215 shares or 1.11% of the stock. The Texas-based Wfg Advisors Lp has invested 0% in United Therapeutics Corporation (NASDAQ:UTHR). Pnc Fincl Services Gp Inc, a Pennsylvania-based fund reported 2,277 shares. Sumitomo Mitsui Asset Management Limited, a Japan-based fund reported 3,194 shares. Principal Gp Inc accumulated 0.02% or 168,272 shares. Orrstown Serv holds 0% or 10 shares in its portfolio.
Insider Transactions: Since June 2, 2016, the stock had 0 insider purchases, and 27 insider sales for $5.64 million net activity. $142,064 worth of United Therapeutics Corporation (NASDAQ:UTHR) was sold by ROTHBLATT MARTINE A on Thursday, July 7. DWEK RAYMOND sold $356,448 worth of stock. 5,000 shares with value of $613,627 were sold by PATUSKY CHRISTOPHER on Thursday, September 1. 2,000 United Therapeutics Corporation (NASDAQ:UTHR) shares with value of $231,247 were sold by Thompson Tommy G.
The stock decreased 4.65% or $6.17 during the last trading session, hitting $126.57. About 520,077 shares traded hands. United Therapeutics Corporation (NASDAQ:UTHR) has risen 13.02% since April 26, 2016 and is uptrending. It has outperformed by 7.76% the S&P500.
United Therapeutics Corporation is a biotechnology company. The company has a market cap of $5.30 billion. The Firm is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. It has a 8.53 P/E ratio. The Company’s therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 Inhibitor and Monoclonal Antibody (MAb).
According to Zacks Investment Research, “UTD THERAPEUTIC is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. These products include pharmaceuticals, arginine products and telemedicine services.”
Analysts await United Therapeutics Corporation (NASDAQ:UTHR) to report earnings on February, 23. They expect $3.56 EPS, up 61.09% or $1.35 from last year’s $2.21 per share. UTHR’s profit will be $149.07 million for 8.89 P/E if the $3.56 EPS becomes a reality. After $3.63 actual EPS reported by United Therapeutics Corporation for the previous quarter, Wall Street now forecasts -1.93% negative EPS growth.
More notable recent United Therapeutics Corporation (NASDAQ:UTHR) news were published by: Fool.com which released: “Better Buy: Organovo Holdings, Inc. vs. United Therapeutics Corporation” on October 14, 2016, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating United ..” published on October 31, 2016, Prnewswire.com published: “United Therapeutics Corporation Announces Executive Leadership Changes” on April 28, 2016. More interesting news about United Therapeutics Corporation (NASDAQ:UTHR) were released by: Prnewswire.com and their article: “United Therapeutics Corporation To Present At The 2016 Wedbush PacGrow ..” published on August 10, 2016 as well as Prnewswire.com‘s news article titled: “United Therapeutics Corporation Reports Second Quarter 2016 Financial Results” with publication date: July 28, 2016.
United Therapeutics Corporation, incorporated on June 26, 1996, is a biotechnology company. The Firm is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb). The Firm is engaged in early-stage research and development into a range of organ transplantation-related technologies. It is also engaged in a range of research and development activities in xenotransplantation, regenerative medicine and ex-vivo lung perfusion, all of which are intended to supply transplantable organs and tissues. These activities are focused on lungs, but are also being applied to other organs, such as hearts and kidneys.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.